We read with interest the letter to the editor titled “Comments on A Conceptual Framework for Life-Cycle Health Technology Assessment” in response to our recent article published in
Value in Health.
1
We thank the authors for their analysis of our work and for their endorsement of the life-cycle health technology assessment (LC-HTA) framework. In response, we clarify the need for de novo model development as part of research-oriented market access, as well as some critical aspects of the risk-based price.